Keywords
ISCHEMIC CARDIOPATHY
SMOKING HABITS
How to Cite
Abstract
Several authors have demonstrated an association between the exposure to certain risk factors and the increase in costs of drug treatments for cardiovascular diseases. The present study analyses the pharmacological treatment costs of patients at a Coronary Care unit of dr. Jose Penna Hospital in the city of Bahia Blanca (Argentina) between March 2008 and May 2010. We analyze the daily middle cost variation of pharmacological treatments for ischemic cardiopathy patients with (or without)
smoking habits. It has been observed that the cardiopathy isquemic patients with smoking habits face an increased cost associated with/due to higher direct costs in pharmacological treatments than those who were not exposed to smoking. At the same time, the estimated costs for each group of patients show variability depending on being estimated to maximum or minimum prices, as a result of the wide dispersion of prices seen in the pharmaceutical market.
References
World Health Organization. The World Health Report 2002. Reducing risks, promoting healthy life. Geneva: WHO; 2002. Hallado en http://www.who.int/entity/whr/2002/en/whr02_en.pdf. Acceso el 10 de marzo de 2010.
Rubinstein, A., Colantonio, L., Bardach, A., Caporale, J., Martí, S. G., Kopitowski, K., Alcaraz, A., Gibbons, L., Augustovski, F., Pichón-Rivière, A. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010 Oct 20; 10: 627.
Levenson, J. W., Skerrett, P. J., Gaziano, J. M. Reducing the global burden of cardiovascular disease: the role of risk factors. Preventive Cardiology 2002; 5(4): 188–199.
Lloyd-Jones, D. M., Evans, J. C., Levy, D. Hypertension in adults across the age spectrum: current outcomes and control in the community. J Am Med Assoc. 2005; 294(4): 466–72.
Huxley, R., Barzi, F., Woodward, M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: metaanalysis of 37 prospective cohort studies. Br Med J. 2006; 332(7533):73–8.
Bogers, R. P., Bemelmans, W. J., Hoogenveen, R. T., Boshuizen, H. C., Woodward, M., Knekt, P. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300000 persons. Arch Intern Med. 2007; 167(16):1720–8.
Ezzati, M., López, A. D. Smoking and oral tobacco use. En: Ezzati M, López Ad, Rodgers A, Murray Cjl, ed. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: World Health Organization; 2004: 883–957.
He, F. J., Nowson, C. A., Macgregor, G. A. Fruit and vegetable consumption and stroke: metaanalysis of cohort studies. Lancet. 2006; 367(9507):320–6.
Hu, G., Tuomilehto, J., Silventoinen, K., Sarti, C., Mannisto, S., Jousilahti, P. Body mass index, waist circumference, and waist-hip ratio on the risk of total and type-specific stroke. Arch Intern Med. 2007; 167(13):1420–7.
Amarenco, P., Labreuche, J., Lavallee, P., Touboul, P. J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004; 35(12):2902–9.
Lee, C. D., Folsom, A. R., Blair, S. N. Physical activity and stroke risk: a meta-analysis. Stroke. 2003; 34(10):2475–81.
Yusuf, S., Reddy, S., Ounpuu, S., Anand, S. Global burden of cardiovascular diseases: part I. Circulation. 2001; 104(22):2746-53.
Lightwood, J. The economics of smoking and cardiovascular disease. Prog Cardiovasc Dis. 2003; 46(1):39-78.
Probstfield, J. L. How cost-effective are new preventive strategies for cardiovascular disease? Am J Cardiol. 2003;91(10A):22g-27g.
Fishman, P. A., Thompson, E. E., Merikle, E., Curry, S. J. Changes in health care costs before and after smoking cessation. Nicotine Tob Res. 2006; 8(3):393-401.
Fishman, P. A., Khan, Z. M., Thompson, E. E., Curry, S. J. Health care costs among smokers, former smokers, and never smokers in an HMO. Health Serv Res. 2003; 38(2):733-49.
Rubinstein, A., Colantonio, L., Bardach, A., Caporale, J., García, M. S., Kopitowski, K. Estimación de la carga de las enfermedades cardiovasculares atribuible a factores de riesgo modificables en Argentina. Rev Panam Salud Publica; 27(4): 237-245.
Russell, M. W., Huse, D. M., Drowns, S., Hamel, E. C., Hartz, S. C. Direct medical costs of coronary artery disease in the United States. The American Journal of Cardiology, vol. 81, mayo 1998, pp. 1110-1115.
Leal, J., Luengo-Fernandez, R., Gray, A., Petersen, S., Rayner, M. Economic burden of cardiovascular diseases in the enlarged European Union. European Heart Journal. 2006.
Bovet, P., Shamlaye, C., Gabriel, A., Riesen, W., Paccaud, F. Prevalence of cardiovascular risk factors in a middle-income country. BMC Public Health. 2006; 6:9.
Ripari, N., Vega, E., Elorza, M., Moscoso, N., Palma, S., Budassi, N. The role of the pharmacist in the determination of pharmacotherapy costs. Pharmaceuticals Policy and Law (2010), 12: 313-9.
WHO Collaborating Centre for Drug Statistics Methodology and Norwegian Institute of Public Health. ATC/DDD Index 2010 [Internet]. Disponible en: http://www.whocc.no/atc_ddd_index/ (Acceso: noviembre 2010).
Grupo Alfa Beta. Manual farmacéutico online [Internet]. Disponible en: http://www.alfabeta.net/ (Acceso: septiembre-octubre 2010).
Kairos. Revista de ciencia y tecnología para la farmacia del siglo XXI [Internet]. Disponible en: http://www.kairosweb.com/default.asp (Acceso: octubre de 2010).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2011 Nadia Vanina Ripari, María Eugenia Elorza, Nebel Silvana Moscoso, María Elena Vega